Targeting cell signaling pathways for drug discovery: An old lock needs a new key
✍ Scribed by Bharat B. Aggarwal; Gautam Sethi; Veera Baladandayuthapani; Sunil Krishnan; Shishir Shishodia
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 274 KB
- Volume
- 102
- Category
- Article
- ISSN
- 0730-2312
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
In this age of targeted therapy, the failure of most current drug‐discovery efforts to yield safe, effective, and inexpensive drugs has generated widespread concern. Successful drug development has been stymied by a general focus on target selection rather than clinical safety and efficacy. The very process of validating the targets themselves is inefficient and in many cases leads to drugs having poor efficacy and undesirable side effects. Indeed, some rationally designed drugs (e.g., inhibitors of receptor tyrosine kinases, tumor necrosis factor (TNF), cyclooxygenase‐2 (COX‐2), vascular endothelial growth factor (VEGF), bcr‐abl, and proteasomes) are ineffective against cancers and other inflammatory conditions and produce serious side effects. Since any given cancer carries mutations in an estimated 300 genes, this raises an important question about how effective these targeted therapies can ever be against cancer. Thus, it has become necessary to rethink drug development strategies. This review analyzes the shortcomings of rationally designed target‐specific drugs against cancer cell signaling pathways and evaluates the available options for future drug development. J. Cell. Biochem. 102: 580–592, 2007. © 2007 Wiley‐Liss, Inc.